Leonid G. Zaslavsky
Saint Petersburg, SPE, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 08, 2025
Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: April 27, 2024
Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 10, 2023
Treatment of cognitive, behavioral and mental disorders in patients with vascular dementia: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: July 25, 2023
Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: April 21, 2023
Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: February 17, 2022
The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: January 15, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026